Fennec Pharmaceuticals Expands PEDMARK® Use to Adult Head & Neck Cancer Patients
Event summary
- Fennec Pharmaceuticals presented real-world data supporting PEDMARK® use in adults with head & neck cancers at the 2026 Multidisciplinary Head and Neck Cancers Symposium.
- Study of 15 adults showed PEDMARK® could be safely administered ≥6 hours after cisplatin without disrupting treatment.
- Majority of high-risk patients receiving PEDMARK® demonstrated no measurable hearing loss during or after treatment.
- PEDMARK® is currently approved for pediatric patients but shows potential for broader adult cancer applications.
The big picture
Fennec Pharmaceuticals is strategically positioning PEDMARK® for broader use beyond pediatric patients, addressing a critical survivorship gap in adult cancer treatment. The real-world data supports its potential to prevent cisplatin-induced hearing loss without compromising antitumor activity, a significant advantage in the oncology market. This expansion could substantially increase PEDMARK®'s addressable market, currently limited to pediatric applications.
What we're watching
- Regulatory Expansion
- Whether Fennec can secure FDA approval for PEDMARK® in adult head & neck cancer patients following these positive real-world results.
- Market Penetration
- The pace at which PEDMARK® adoption will grow among adult cancer patients, given its current pediatric focus.
- Competitive Dynamics
- How this expansion affects Fennec's competitive position against other otoprotective therapies in development.
Our editorial coverage:
Related topics